# Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Source: https://onco.cc/trials/nct03936153/  
OnCo record `nct03936153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abexinostat in diffuse large b-cell lymphoma, run by Xynomic Pharmaceuticals, Inc., now recruiting.

## Summary

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT03936153 by Xynomic Pharmaceuticals, Inc., with 170 participants planned, started 2020-01-20 and due to reach its primary completion in 2026-07-31. Interventions recorded: abexinostat. Conditions listed: Diffuse Large B-cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03936153
- Phase: 2
- Setting: An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor: Xynomic Pharmaceuticals, Inc.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT03936153: https://clinicaltrials.gov/study/NCT03936153

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct03936153.json